Investigating psychotropic properties of antiepileptic drugs

Expert Review of Neurotherapeutics

Volumn 13, Issue 6, 2013, Pages 639-646

  Mula, Marco ^a  

^a Division of Neurology   (Italy)

Author keywords

antiepileptic drugs; anxiety disorders; bipolar disorder; epilepsy; mania; valnoctamide

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; ANTICONVULSIVE AGENT; BRIVARACETAM; CARBAMAZEPINE; ESLICARBAZEPINE ACETATE; ETIRACETAM; GABAPENTIN; GANAXOLONE; GLUTAMATE RECEPTOR; HARKOSERIDE; LAMOTRIGINE; NEUROSTEROID; OXCARBAZEPINE; PERAMPANEL; PHENYTOIN; PREGABALIN; PSYCHOTROPIC AGENT; RETIGABINE; RISPERIDONE; RUFINAMIDE; SELETRACETAM; TOPIRAMATE; VALNOCTAMIDE; VALPROIC ACID; VALPROMIDE; VIGABATRIN; ZONISAMIDE;

ADD ON THERAPY; ANTICONVULSANT ACTIVITY; AUDITORY HALLUCINATION; BEHAVIOR DISORDER; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR II DISORDER; CONFUSION; DRUG ACTIVITY; DRUG MECHANISM; DRUG TRANSFORMATION; EPILEPSY; EXCITOTOXICITY; FOCAL EPILEPSY; GENERALIZED ANXIETY DISORDER; HUMAN; MAJOR DEPRESSION; MANIA; NERVE DEGENERATION; NEUROPHARMACOLOGY; NEUROTRANSMISSION; NONHUMAN; PANIC; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTTRAUMATIC STRESS DISORDER; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOCIAL PHOBIA; TERATOGENICITY; TRANQUILIZING ACTIVITY; VISUAL HALLUCINATION;

ANIMALS; ANTICONVULSANTS; HUMANS; PSYCHOTROPIC DRUGS;

EID: 84879105333     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.13.57     Document Type: Review

References (112)

1. Bialer M. Why are antiepileptic drugs used for nonepileptic conditions? Epilepsia 53(Suppl. 7), 26-33 (2012).
2. Johannessen Landmark C. Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs 22(1), 27-47 (2008). (Pubitemid 350243365)
3. Mula M, Sander JW. Negative effects of antiepileptic drugs on mood in patients with epilepsy. Drug Saf. 30(7), 555-567 (2007). (Pubitemid 47037315)
4. Chris Sackellares J, Jacqueline Kwong W, Vuong A, Hammer AE, Barrett PS. Lamotrigine monotherapy improves health-related quality of life in epilepsy: a double-blind comparison with valproate. Epilepsy Behav. 3(4), 376-382 (2002). (Pubitemid 35256237)
5. Lin JJ, Mula M, Hermann BP. Uncovering the neurobehavioural comorbidities of epilepsy over the lifespan. Lancet 380(9848), 1180-1192 (2012).
6. Sanacora G, Saricicek A. GABAergic contributions to the pathophysiology of depression and the mechanism of antidepressant action. CNS Neurol. Disord. Drug Targets 6(2), 127-140 (2007). (Pubitemid 46681773)
7. Comai S, Tau M, Gobbi G. The psychopharmacology of aggressive behavior: a translational approach: part 1: neurobiology. J. Clin. Psychopharmacol. 32(1), 83-94 (2012).
8. Mula M, Monaco F. Antiepileptic drugs and psychopathology of epilepsy: an update. Epileptic Disord. 11(1), 1-9 (2009).
9. Mula M. New antiepileptic drugs: molecular targets. Cent. Nerv. Syst. Agents Med. Chem. 9(2), 79-86 (2009).
10. Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs. Nat. Rev. Neurosci. 5(7), 553-564 (2004). (Pubitemid 38868551)
11. Mula M. GABAergic drugs in the treatment of epilepsy: modern or outmoded? Future Med. Chem. 3(2), 177-182 (2011).
12. Farrant M, Nusser Z. Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors. Nat. Rev. Neurosci. 6(3), 215-229 (2005). (Pubitemid 40342416)
13. Carta MG, Bhat KM, Preti A. GABAergic neuroactive steroids: a new frontier in bipolar disorders? Behav. Brain Funct. 8, 61 (2012).
14. Marx CE, Stevens RD, Shampine LJ et al. Neuroactive steroids are altered in schizophrenia and bipolar disorder: relevance to pathophysiology and therapeutics. Neuropsychopharmacology 31(6), 1249-1263 (2006). (Pubitemid 43971841)
15. Pieribone VA, Tsai J, Soufflet C et al. Clinical evaluation of ganaxolone in pediatric and adolescent patients with refractory epilepsy. Epilepsia 48(10), 1870-1874 (2007). (Pubitemid 47537451)
16. Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res. 92(2-3), 89-124 (2010).
17. Hu AQ, Wang ZM, Lan DM et al. Inhibition of evoked glutamate release by neurosteroid allopregnanolone via inhibition of l-type calcium channels in rat medial prefrontal cortex. Neuropsychopharmacology 32(7), 1477-1489 (2007).
18. Mula M. Recent and future antiepileptic drugs and their impact on cognition: what can we expect? Expert Rev. Neurother. 12(6), 667-671 (2012).
19. Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI). Epilepsy Res. 103(1), 2-30 (2013).
20. No authors listed. Gamma-aminobutyric acid (GABA), monograph. Altern. Med. Rev. 12(3), 274-279 (2007).
21. Altamura CA, Mauri MC, Ferrara A, Moro AR, D'Andrea G, Zamberlan F. Plasma and platelet excitatory amino acids in psychiatric disorders. Am. J. Psychiatry 150(11), 1731-1733 (1993). (Pubitemid 23325960)
22. Mauri MC, Ferrara A, Boscati L et al. Plasma and platelet amino acid concentrations in patients affected by major depression and under fluvoxamine treatment. Neuropsychobiology 37(3), 124-129 (1998). (Pubitemid 28171767)
23. Sheline YI. Hippocampal atrophy in major depression: a result of depression-induced neurotoxicity? Mol. Psychiatry 1(4), 298-299 (1996).
24. Sapolsky RM. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch. Gen. Psychiatry 57(10), 925-935 (2000).
25. Kendell SF, Krystal JH, Sanacora G. GABA and glutamate systems as therapeutic targets in depression and mood disorders. Expert Opin. Ther. Targets 9(1), 153-168 (2005). (Pubitemid 40331202)
26. Meldrum BS, Rogawski MA. Molecular targets for antiepileptic drug development. Neurotherapeutics 4(1), 18-61 (2007). (Pubitemid 46107329)
27. Lee CY, Fu WM, Chen CC, Su MJ, Liou HH. Lamotrigine inhibits postsynaptic AMPA receptor and glutamate release in the dentate gyrus. Epilepsia 49(5), 888-897 (2008).
28. Gibbs JW 3rd, Sombati S, DeLorenzo RJ, Coulter DA. Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia 41(Suppl. 1), S10-S16 (2000).
29. Meldrum BS. Lamotrigine-a novel approach. Seizure 3(Suppl. A), 41-45 (1994).
30. Cunningham MO, Jones RS. The anticonvulsant, lamotrigine decreases spontaneous glutamate release but increases spontaneous GABA release in the rat entorhinal cortex in vitro. Neuropharmacology 39(11), 2139-2146 (2000). (Pubitemid 30645637)
31. Wang SJ, Sihra TS, Gean PW. Lamotrigine inhibition of glutamate release from isolated cerebrocortical nerve terminals (synaptosomes) by suppression of voltage-activated calcium channel activity. Neuroreport 12(10), 2255-2258 (2001). (Pubitemid 32646283)
32. Gay PE, Mecham GF, Coskey JS, Sadler T, Thompson JA. Behavioral effects of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). Psychol. Rep. 77(3 Pt 2), 1208-1210 (1995).
33. Ketter TA, Post RM, Theodore WH. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology 53(5 Suppl. 2), S53-S67 (1999). (Pubitemid 29442167)
34. Frye MA. Clinical practice. Bipolar disorder-a focus on depression. N. Engl. J. Med. 364(1), 51-59 (2011).
35. Schindler F, Anghelescu IG. Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: a randomized, open-label study. Int. Clin. Psychopharmacol. 22(3), 179-182 (2007). (Pubitemid 46559875)
36. Ettinger AB, Kustra RP, Hammer AE. Effect of lamotrigine on depressive symptoms in adult patients with epilepsy. Epilepsy Behav. 10(1), 148-154 (2007). (Pubitemid 46132163)
37. Tritt K, Nickel C, Lahmann C et al. Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. J. Psychopharmacol. (Oxford) 19(3), 287-291 (2005). (Pubitemid 40694947)
38. Reich DB, Zanarini MC, Bieri KA. A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder. Int. Clin. Psychopharmacol. 24(5), 270-275 (2009).
39. Perucca P, Mula M. Antiepileptic drug effects on mood and behavior: molecular targets. Epilepsy Behav. 26(3), 440-449 (2013).
40. Mula M, Trimble MR, Lhatoo SD, Sander JW. Topiramate and psychiatric adverse events in patients with epilepsy. Epilepsia 44(5), 659-663 (2003). (Pubitemid 36554633)
41. Nickel C, Lahmann C, Tritt K et al. Topiramate in treatment of depressive and anger symptoms in female depressive patients: a randomized, double-blind, placebo-controlled study. J. Affect. Disord. 87(2-3), 243-252 (2005). (Pubitemid 41039946)
42. Nickel MK, Nickel C, Mitterlehner FO et al. Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study. J. Clin. Psychiatry 65(11), 1515-1519 (2004).
43. Nickel MK, Nickel C, Kaplan P et al. Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study. Biol. Psychiatry 57(5), 495-499 (2005). (Pubitemid 40311984)
44. Leombruni P, Lavagnino L, Fassino S. Treatment of obese patients with binge eating disorder using topiramate: a review. Neuropsychiatr. Dis. Treat. 5, 385-392 (2009).
45. Mula M, Pini S, Cassano GB. The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence. J. Clin. Psychopharmacol. 27(3), 263-272 (2007). (Pubitemid 46763308)
46. Delbello MP, Findling RL, Kushner S et al. A pilot controlled trial of topiramate for mania in children and adolescents with bipolar disorder. J. Am. Acad. Child Adolesc. Psychiatry 44(6), 539-547 (2005). (Pubitemid 40720953)
47. Roy Chengappa KN, Schwarzman LK, Hulihan JF, Xiang J, Rosenthal NR; Clinical Affairs Product Support Study-168 Investigators. Adjunctive topiramate therapy in patients receiving a mood stabilizer for bipolar I disorder: a randomized, placebo-controlled trial. J. Clin. Psychiatry 67(11), 1698-1706 (2006). (Pubitemid 44955149)
48. Lindley SE, Carlson EB, Hill K. A randomized, double-blind, placebo-controlled trial of augmentation topiramate for chronic combat-related posttraumatic stress disorder. J. Clin. Psychopharmacol. 27(6), 677-681 (2007). (Pubitemid 351339456)
49. Tucker P, Trautman RP, Wyatt DB et al. Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry 68(2), 201-206 (2007). (Pubitemid 46362640)
50. Mula M, Cavanna AE, Monaco F. Psychopharmacology of topiramate: from epilepsy to bipolar disorder. Neuropsychiatr. Dis. Treat. 2(4), 475-488 (2006). (Pubitemid 46321877)
51. French JA, Krauss GL, Biton V et al. Adjunctive perampanel for refractory partial-onset seizures: randomized Phase III study 304. Neurology 79(6), 589-596 (2012).
52. Krauss GL, Serratosa JM, Villanueva V et al. Randomized Phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology 78(18), 1408-1415 (2012).
53. Rektor I, Krauss GL, Bar M et al. Perampanel Study 207: long-term open-label evaluation in patients with epilepsy. Acta Neurol. Scand. 126(4), 263-269 (2012).
54. Krauss GL, Perucca E, Ben-Menachem E et al. Perampanel, a selective, noncompetitive a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partialonset seizures: interim results from Phase III, extension study 307. Epilepsia 54(1), 126-134 (2013).
55. French JA, Krauss GL, Steinhoff BJ et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global Phase III study 305. Epilepsia 54(1), 117-125 (2013).
56. El-Mallakh RS, Huff MO. Mood stabilizers and ion regulation. Harv. Rev. Psychiatry 9(1), 23-32 (2001). (Pubitemid 32127439)
57. Mogilnicka E, Czyrak A, Maj J. Dihydropyridine calcium channel antagonists reduce immobility in the mouse behavioral despair test; antidepressants facilitate nifedipine action. Eur. J. Pharmacol. 138(3), 413-416 (1987). (Pubitemid 17094316)
58. Galeotti N, Bartolini A, Ghelardini C. Blockade of intracellular calcium release induces an antidepressant-like effect in the mouse forced swimming test. Neuropharmacology 50(3), 309-316 (2006). (Pubitemid 43184359)
59. Quintero JE, Dooley DJ, Pomerleau F, Huettl P, Gerhardt GA. Amperometric measurement of glutamate release modulation by gabapentin and pregabalin in rat neocortical slices: role of voltagesensitive Ca2+ a2d-1 subunit. J. Pharmacol. Exp. Ther. 338(1), 240-245 (2011).
60. Dooley DJ, Mieske CA, Borosky SA. Inhibition of K(+)-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neurosci. Lett. 280(2), 107-110 (2000). (Pubitemid 30109144)
61. Farber NB, Jiang XP, Heinkel C, Nemmers B. Antiepileptic drugs and agents that inhibit voltage-gated sodium channels prevent NMDA antagonist neurotoxicity. Mol. Psychiatry 7(7), 726-733 (2002). (Pubitemid 34984950)
62. Cipriani A, Barbui C, Salanti G et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet 378(9799), 1306-1315 (2011).
63. Mula M, Monaco F. Phenytoin and other hydantoins: clinical efficacy and use in psychiatric disorders. In: Antiepileptic Drugs (5th Edition). Levy R, Mattson R, Meldrum B, Perucca E (Eds). Lippincott William & Wilkins, Baltimore, MD, USA, 600-604 (2002).
64. Rosa AR, Fountoulakis K, Siamouli M, Gonda X, Vieta E. Is anticonvulsant treatment of mania a class effect? Data from randomized clinical trials. CNS Neurosci. Ther. 17(3), 167-177 (2011).
65. Fornaro M, Martino M, Dalmasso B et al. An open pilot study of zonisamide augmentation in major depressive patients not responding to a low dose trial with duloxetine: preliminary results on tolerability and clinical effects. Ann. Gen. Psychiatry 10(1), 23 (2011).
66. Dauphinais D, Knable M, Rosenthal J, Polanski M, Rosenthal N. Zonisamide for bipolar disorder, mania or mixed states: a randomized, double blind, placebo-controlled adjunctive trial. Psychopharmacol. Bull. 44(1), 5-17 (2011).
67. Stahl SM. Mechanism of action of 2 ligands: voltage sensitive calcium channel (VSCC) modulators. J. Clin. Psychiatry 65(8), 1033-1034 (2004).
68. Mico JA, Prieto R. Elucidating the mechanism of action of pregabalin: a(2)d as a therapeutic target in anxiety. CNS Drugs 26(8), 637-648 (2012).
69. Montgomery S, Chatamra K, Pauer L, Whalen E, Baldinetti F. Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder. Br. J. Psychiatry 193(5), 389-394 (2008).
70. Kasper S, Herman B, Nivoli G et al. Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. Int. Clin. Psychopharmacol. 24(2), 87-96 (2009).
71. Feltner DE, Liu-Dumaw M, Schweizer E, Bielski R. Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study. Int. Clin. Psychopharmacol. 26(4), 213-220 (2011).
72. Greist JH, Liu-Dumaw M, Schweizer E, Feltner D. Efficacy of pregabalin in preventing relapse in patients with generalized social anxiety disorder: results of a double-blind, placebo-controlled 26-week study. Int. Clin. Psychopharmacol. 26(5), 243-251 (2011).
73. Englisch S, Esser A, Enning F, Hohmann S, Schanz H, Zink M. Augmentation with pregabalin in schizophrenia. J. Clin. Psychopharmacol. 30(4), 437-440 (2010).
74. Showraki M. Pregabalin in the treatment of depression. J. Psychopharmacol. (Oxford) 21(8), 883-884 (2007). (Pubitemid 350029196)
75. Vieta E, Manuel Goikolea J, Martinez-Aran A et al. A double-blind, randomized, placebo-controlled, prophylaxis study of adjunctive gabapentin for bipolar disorder. J. Clin. Psychiatry 67(3), 473-477 (2006).
76. Schifano F, D'Offizi S, Piccione M et al. Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data. Psychother. Psychosom. 80(2), 118-122 (2011).
77. Rogawski MA. KCNQ2/KCNQ3 K+ channels and the molecular pathogenesis of epilepsy: implications for therapy. Trends Neurosci. 23(9), 393-398 (2000).
78. Kobayashi T, Hirai H, Iino M et al. Inhibitory effects of the antiepileptic drug ethosuximide on G protein-activated inwardly rectifying K+ channels. Neuropharmacology 56(2), 499-506 (2009).
79. Dooley DJ, Donovan CM, Pugsley TA. Stimulus-dependent modulation of [(3)H] norepinephrine release from rat neocortical slices by gabapentin and pregabalin. J. Pharmacol. Exp. Ther. 295(3), 1086-1093 (2000).
80. Danielsson BR, Lansdell K, Patmore L, Tomson T. Effects of the antiepileptic drugs lamotrigine, topiramate and gabapentin on hERG potassium currents. Epilepsy Res. 63(1), 17-25 (2005). (Pubitemid 40220335)
81. Madeja M, Margineanu DG, Gorji A et al. Reduction of voltage-operated potassium currents by levetiracetam: a novel antiepileptic mechanism of action? Neuropharmacology 45(5), 661-671 (2003). (Pubitemid 36980822)
82. Deeks ED. Retigabine (ezogabine): in partial-onset seizures in adults with epilepsy. CNS Drugs 25(10), 887-900 (2011).
83. Czuczwar SJ, Patsalos PN. The new generation of GABA enhancers. Potential in the treatment of epilepsy. CNS Drugs 15(5), 339-350 (2001). (Pubitemid 32487991)
84. Barrese V, Miceli F, Soldovieri MV et al. Neuronal potassium channel openers in the management of epilepsy: role and potential of retigabine. Clin. Pharmacol. 2, 225-236 (2010).
85. Dencker D, Husum H. Antimanic efficacy of retigabine in a proposed mouse model of bipolar disorder. Behav. Brain Res. 207(1), 78-83 (2010).
86. Korsgaard MP, Hartz BP, Brown WD, Ahring PK, Strobaek D, Mirza NR. Anxiolytic effects of Maxipost (BMS-204352) and retigabine via activation of neuronal Kv7 channels. J. Pharmacol. Exp. Ther. 314(1), 282-292 (2005). (Pubitemid 41058265)
87. Porter RJ, Partiot A, Sachdeo R, Nohria V, Alves WM; 205 Study Group. Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology 68(15), 1197-1204 (2007). (Pubitemid 46608467)
88. Brodie MJ, Lerche H, Gil-Nagel A et al.; RESTORE 2 Study Group. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology 75(20), 1817-1824 (2010).
89. French JA, Abou-Khalil BW, Leroy RF et al.; RESTORE 1/Study 301 Investigators. Randomized, double-blind, placebocontrolled trial of ezogabine (retigabine) in partial epilepsy. Neurology 76(18), 1555-1563 (2011).
90. Potiga. Precribing information. GlaxoSmithKline, Research Triangle Park, NC, USA, 29 June 2012.
91. Hilfiker S, Pieribone VA, Czernik AJ, Kao HT, Augustine GJ, Greengard P. Synapsins as regulators of neurotransmitter release. Philos. Trans. R. Soc. Lond. B, Biol. Sci. 354(1381), 269-279 (1999). (Pubitemid 29365600)
92. Custer KL, Austin NS, Sullivan JM, Bajjalieh SM. Synaptic vesicle protein 2 enhances release probability at quiescent synapses. J. Neurosci. 26(4), 1303-1313 (2006). (Pubitemid 43237062)
93. Lynch BA, Lambeng N, Nocka K et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl Acad. Sci. USA 101(26), 9861-9866 (2004). (Pubitemid 38869327)
94. Muralidharan A, Bhagwagar Z. Potential of levetiracetam in mood disorders: a preliminary review. CNS Drugs 20(12), 969-979 (2006). (Pubitemid 44912706)
95. Zhang W, Connor KM, Davidson JR. Levetiracetam in social phobia: a placebo controlled pilot study. J. Psychopharmacol. (Oxford) 19(5), 551-553 (2005). (Pubitemid 41392309)
96. Saricicek A, Maloney K, Muralidharan A et al. Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 72(6), 744-750 (2011).
97. Stein MB, Ravindran LN, Simon NM et al. Levetiracetam in generalized social anxiety disorder: a double-blind, randomized controlled trial. J. Clin. Psychiatry 71(5), 627-631 (2010).
98. Mattes JA. Levetiracetam in patients with impulsive aggression: a double-blind, placebo-controlled trial. J. Clin. Psychiatry 69(2), 310-315 (2008). (Pubitemid 351469275)
99. Mula M, Trimble MR, Yuen A, Liu RS, Sander JW. Psychiatric adverse events during levetiracetam therapy. Neurology 61(5), 704-706 (2003). (Pubitemid 37082613)
100. White JR, Walczak TS, Leppik IE et al. Discontinuation of levetiracetam because of behavioral side effects: a case-control study. Neurology 61(9), 1218-1221 (2003). (Pubitemid 37377540)
101. Helmstaedter C, Mihov Y, Toliat MR et al. Genetic variation in dopaminergic activity is associated with the risk for psychiatric side effects of levetiracetam. Epilepsia 54(1), 36-44 (2013).
102. Post RM, Silberstein SD. Shared mechanisms in affective illness, epilepsy, and migraine. Neurology 44(10 Suppl. 7), S37-S47 (1994).
103. Kanner AM. Depression and epilepsy: a bidirectional relation? Epilepsia 52(Suppl. 1), 21-27 (2011).
104. Machado-Vieira R, Kapczinski F, Soares JC. Perspectives for the development of animal models of bipolar disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 28(2), 209-224 (2004). (Pubitemid 38130126)
105. Amann B, Grunze H. Neurochemical underpinnings in bipolar disorder and epilepsy. Epilepsia 46(Suppl. 4), 26-30 (2005). (Pubitemid 40847380)
106. Hafeman DM, Chang KD, Garrett AS, Sanders EM, Phillips ML. Effects of medication on neuroimaging findings in bipolar disorder: an updated review. Bipolar Disord. 14(4), 375-410 (2012).
107. Post RM, Weiss SR. A speculative model of affective illness cyclicity based on patterns of drug tolerance observed in amygdalakindled seizures. Mol. Neurobiol. 13(1), 33-60 (1996). (Pubitemid 126733048)
108. Potschka H, Feuerstein TJ, Loscher W. Gabapentin-lactam, a close analogue of the anticonvulsant gabapentin, exerts convulsant activity in amygdala kindled rats. Naunyn Schmiedebergs Arch. Pharmacol. 361(2), 200-205 (2000). (Pubitemid 30062453)
109. Mula M. Topiramate and cognitive impairment: evidence and clinical implications. Ther. Adv. Drug Saf. 3(6), 279-289 (2012).
110. Bersudsky Y, Applebaum J, Gaiduk Y et al. Valnoctamide as a valproate substitute with low teratogenic potential in mania: a double-blind, controlled, add-on clinical trial. Bipolar Disord. 12(4), 376-382 (2010).
111. Zullino DF, Khazaal Y, Hättenschwiler J, Borgeat F, Besson J. Anticonvulsant drugs in the treatment of substance withdrawal. Drugs Today 40(7), 603-619 (2004). (Pubitemid 39281177)
112. Denis C, Fatseas M, Lavie E, Auriacombe M. Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings. Cochrane Database Syst. Rev. 3, CD005194 (2006).